PSMA PET Imaging Market Overview
The global PSMA PET Imaging Market was valued at USD 1 billion in 2025 and is projected to reach USD 2 billion by 2035, registering a CAGR of 9.3% during the forecast period from 2026 to 2035. The market growth is being driven by the increasing prevalence of prostate cancer, rising adoption of advanced molecular imaging technologies, growing demand for accurate cancer diagnosis, and expanding use of PSMA-targeted radiopharmaceuticals in oncology care.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has emerged as an advanced diagnostic technology for detecting and managing prostate cancer. PSMA PET imaging enables highly precise visualization of prostate cancer cells by targeting PSMA expression, helping physicians improve disease staging, treatment planning, recurrence detection, and therapy monitoring. The increasing need for early and accurate cancer diagnosis is significantly contributing to the adoption of PSMA PET imaging technologies.
The market is benefiting from rapid advancements in nuclear medicine, radiopharmaceutical development, hybrid imaging technologies, and personalized oncology approaches. Healthcare providers are increasingly adopting PSMA PET imaging as a valuable tool for improving clinical decision-making and optimizing treatment strategies. The integration of PSMA PET with CT and MRI technologies is further enhancing diagnostic accuracy and expanding clinical applications.
Growing investments in prostate cancer research, increasing availability of advanced imaging infrastructure, and expanding reimbursement support for molecular imaging procedures are expected to create new growth opportunities. The rising focus on theranostics, where diagnostic imaging and targeted therapy are combined, is also strengthening the importance of PSMA PET imaging in modern cancer management.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=594047
GE Healthcare
Siemens Healthineers
Canon Medical Systems
Lantheus Holdings
Novartis AG
Blue Earth Diagnostics
Telix Pharmaceuticals
Eli Lilly and Company
Thermo Fisher Scientific
Bracco Imaging
Bayer AG
Jubilant Radiopharma
Curium Pharma
Life Molecular Imaging
Advanced Accelerator Applications
The competitive landscape of the PSMA PET Imaging Market includes major healthcare technology companies, radiopharmaceutical manufacturers, nuclear medicine specialists, and biotechnology organizations. Companies are focusing on developing advanced tracers, improving imaging technologies, expanding production capabilities, and strengthening their presence in the growing field of precision oncology.
Lantheus Holdings has established a strong position in the PSMA PET imaging space through its focus on prostate cancer diagnostic solutions and radiopharmaceutical innovation. Novartis is actively involved in radioligand therapy and PSMA-targeted oncology solutions, while GE Healthcare, Siemens Healthineers, and Canon Medical Systems continue to support market development through advanced PET and hybrid imaging systems.
Strategic collaborations, regulatory approvals, and technological advancements remain important growth strategies among market participants. Companies are investing in next-generation radiotracers, automated imaging workflows, and integrated diagnostic platforms to improve accessibility and clinical efficiency. The increasing adoption of PSMA-based theranostics is encouraging collaboration between imaging companies and pharmaceutical developers.
North America is expected to maintain a dominant position in the global PSMA PET Imaging Market due to advanced healthcare infrastructure, high adoption of molecular imaging technologies, strong oncology research capabilities, and increasing utilization of precision diagnostic methods. The presence of leading radiopharmaceutical companies and established cancer treatment centers further supports regional growth.
Europe is projected to witness steady growth due to increasing investments in nuclear medicine, growing prostate cancer awareness, and expanding access to advanced imaging procedures. Countries across the region are adopting PSMA PET imaging for improved prostate cancer staging and treatment planning.
Asia Pacific is expected to experience significant growth during the forecast period as healthcare infrastructure improves, cancer diagnosis capabilities expand, and investments in advanced imaging technologies increase. Rising prostate cancer cases and growing awareness of precision oncology solutions are expected to support market expansion. South America and the Middle East and Africa are also expected to show gradual growth as healthcare systems continue to develop and access to advanced diagnostic technologies improves.
The PSMA PET Imaging Market is segmented by type, product type, application, procedure type, end user, and region. By type, the market includes Prostate Cancer Diagnosis, Radiotherapy Planning, and Drug Development. Prostate cancer diagnosis represents a major application segment due to the increasing use of PSMA PET imaging for detecting primary tumors, metastatic disease, and biochemical recurrence.
By product type, the market includes Radiopharmaceuticals, Imaging Scanners, and Reagents. Radiopharmaceuticals represent a significant segment due to the growing demand for PSMA-targeted tracers such as Gallium-68 and Fluorine-18-based agents. Imaging scanners also play a crucial role as healthcare providers invest in advanced PET/CT systems to support accurate molecular imaging.
By application, the market covers prostate cancer staging, recurrence detection, treatment planning, and drug development research. Prostate cancer staging and diagnosis remain key applications because PSMA PET imaging provides improved sensitivity compared with conventional imaging methods. Drug development applications are expanding as pharmaceutical companies use PSMA imaging to support clinical trials and evaluate targeted therapies.
By procedure type, the market is divided into Diagnostic Imaging Procedures and Therapeutic Procedures. Diagnostic imaging procedures currently dominate due to widespread clinical use for prostate cancer evaluation. Therapeutic procedures are gaining importance as PSMA imaging becomes increasingly connected with radioligand therapy approaches.
By end user, the market includes Hospitals, Diagnostic Imaging Centers, and Research Institutions. Hospitals represent a major end-user segment due to the increasing integration of PSMA PET imaging into oncology workflows. Diagnostic imaging centers are expanding as demand for specialized molecular imaging services increases, while research institutions contribute through clinical studies and innovation in nuclear medicine.
Recent Developments and Market Trends:
- Increasing prostate cancer prevalence is driving demand for advanced diagnostic imaging solutions.
- PSMA PET imaging is gaining adoption for accurate staging, recurrence detection, and treatment planning.
- Growth in radiopharmaceutical development is strengthening the role of molecular imaging in oncology.
- Hybrid PET/CT and PET/MRI technologies are improving diagnostic accuracy and workflow efficiency.
- Theranostics approaches combining PSMA imaging and targeted therapy are creating new market opportunities.
- Increasing investments in nuclear medicine infrastructure are supporting market expansion.
- Personalized oncology approaches are increasing demand for targeted imaging technologies.
- Pharmaceutical companies are using PSMA PET imaging in clinical trials and drug development programs.
- North America remains a leading market due to advanced healthcare systems and high technology adoption.
- Asia Pacific is emerging as a high-growth region due to improving cancer-care infrastructure and increasing healthcare investments.
Reasons to Buy the Report:
- Understand the current market size, growth trajectory, and forecast of the global PSMA PET Imaging Market.
- Analyze key market segments by type, product type, application, procedure type, end user, and region.
- Evaluate leading companies and competitive strategies in molecular imaging and radiopharmaceutical development.
- Identify growth opportunities associated with prostate cancer diagnosis and precision oncology.
- Examine the impact of technological advancements in PET imaging and radiotracer development.
- Assess regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
- Understand emerging trends in theranostics, hybrid imaging, and targeted cancer management.
- Support strategic planning, investment decisions, partnerships, and market expansion initiatives.
Future Outlook:
The PSMA PET Imaging Market is expected to experience strong and sustained growth through 2035 as healthcare providers increasingly adopt advanced molecular imaging technologies for prostate cancer management. The continued rise in prostate cancer cases, improvements in radiopharmaceutical development, and growing acceptance of precision oncology approaches will remain major growth drivers.
Future market expansion will be influenced by advances in hybrid imaging systems, AI-assisted image analysis, improved tracer availability, and the integration of PSMA PET imaging with targeted radioligand therapies. North America is expected to maintain a leadership position due to strong healthcare infrastructure and technological adoption, while Asia Pacific will provide significant growth opportunities as access to advanced diagnostic technologies improves. Increasing investment in nuclear medicine, oncology research, and personalized treatment strategies will support the market’s progression toward USD 2 billion by 2035.
➤➤Explore Our Latest Related Reports:
